Development Pipeline

AMY01 is a specific combination of exopeptidases, capable of cleaving immunogenic polypeptide chains into single amino acids and dipeptides; safely metabolised digestion products that do not trigger immune responses. The enzyme combination is being developed as a dietary supplement to alleviate symptoms in people suffering from non-celiac gluten sensitivity.

Whilst a range of existing products claim to digest gluten, a strict gluten-free diet is the only effective treatment for non-celiac gluten sensitivity to date. So far, several approaches have failed to target and effectively treat the underlying cause of non-celiac gluten sensitivity and celiac disease, namely gluten immunogenic peptides (GIPs), which derive from incomplete digestion of gluten and trigger inflammatory immune responses. 

Although commercially available enzyme supplements claim to aid the digestion of gluten protein, these claims can be misleading as GIPs underlying pathology are often the byproducts of “gluten digestion”.